Focal deletion of the adenosine A1 receptor in adult mice using an adeno-associated viral vector

被引:0
|
作者
Scammell, TE
Arrigoni, E
Thompson, MA
Ronan, PJ
Saper, CB
Greene, RW
机构
[1] Vet Affairs Med Ctr, Dept Psychiat, Dallas, TX 75216 USA
[2] Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02115 USA
[3] Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA 02215 USA
[4] Childrens Hosp, Div Neurosci, Boston, MA 02115 USA
[5] Univ Texas, SW Med Ctr, Dept Psychiat, Dallas, TX 75216 USA
来源
JOURNAL OF NEUROSCIENCE | 2003年 / 23卷 / 13期
关键词
adenosine; A1; receptor; Cre recombinase; adeno-associated virus; AAV; electrophysiology; patch clamp;
D O I
暂无
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Adenosine is a ubiquitous neuromodulator that increases sleep, inhibits seizures, and promotes neuroprotection. Many of these effects are mediated by A1 receptors, but A1 receptors are expressed in most brain regions, and distinguishing the precise site of action of adenosine is challenging. To test the role of adenosine in different hippocampal regions, we have used the Cre-loxP system and an adeno-associated viral (AAV) vector to focally delete endogenous adenosine A1 receptors in the hippocampus. Microinjection of an AAV vector containing the gene for Cre recombinase induced intense, focal, neuron-specific recombination in reporter mice. In a separate line of mice with loxP sites flanking the major coding exon for the adenosine A1 receptor, this AAV-Cre markedly reduced A1 receptor mRNA and focally abolished the postsynaptic response to adenosine without any change in basic electrophysiologic properties. Adenosine inhibits signaling between CA3 and CA1 neurons, but it is unclear from pharmacologic studies whether this response is caused by presynaptic or postsynaptic effects. Deletion of A1 receptors from CA3 neurons abolished this response to adenosine, but deletion of A1 receptors from CA1 neurons had no effect, demonstrating a presynaptic site of action. This transduction knock-out technique holds enormous potential for dissecting the functions of different CNS pathways.
引用
收藏
页码:5762 / 5770
页数:9
相关论文
共 50 条
  • [1] The adeno-associated viral vector system
    Buening, Hildegard
    HUMAN GENE THERAPY, 2009, 20 (11) : 1353 - 1353
  • [2] Targeting strategies for adeno-associated viral vector
    WANG YiGang1
    2 Institute of Biochemistry and Cell Biology
    ChineseScienceBulletin, 2007, (12) : 1590 - 1599
  • [3] Targeting strategies for adeno-associated viral vector
    Wang YiGang
    Huang Fang
    Cai Rong
    Qian Cheng
    Liu XinYuan
    CHINESE SCIENCE BULLETIN, 2007, 52 (12): : 1590 - 1599
  • [4] Adeno-associated viral (AAV) vectors carrying shRNA for the focal deletion of sleep-active adenosine A2A receptors
    Lazarus, Michael
    Higashi, Tomoko
    Enomoto, Tetsuro
    Yasuda, Hisataka
    Urade, Yoshihiro
    Hayaishi, Osamu
    NEUROSCIENCE RESEARCH, 2009, 65 : S57 - S57
  • [5] Gene Therapy for Choroideremia Using an Adeno-Associated Viral (AAV) Vector
    Barnard, Alun R.
    Groppe, Markus
    MacLaren, Robert E.
    COLD SPRING HARBOR PERSPECTIVES IN MEDICINE, 2015, 5 (03):
  • [6] Hepatotoxicity in Adeno-Associated Viral Vector Gene Therapy
    Jagadisan B.
    Dhawan A.
    Current Hepatology Reports, 2023, 22 (4) : 276 - 290
  • [7] RECOMBINANT ADENO-ASSOCIATED VIRAL VECTOR REFERENCE STANDARDS
    Moullier, Philippe
    Snyder, Richard O.
    METHODS IN ENZYMOLOGY, VOL 507: GENE TRANSFER VECTORS FOR CLINICAL APPLICATION, 2012, 507 : 297 - 311
  • [8] Development of an adeno-associated viral vector for mucopolysaccharidosis IIIC
    O'Leary, Claire
    Antunes, Andre
    Parker, Helen
    Henckaerts, Els
    Linden, Michael
    Wilkinson, Fiona
    Pshezhetsky, Alexey
    Bigger, Brian
    MOLECULAR GENETICS AND METABOLISM, 2015, 114 (02) : S88 - S88
  • [9] Current issues in adeno-associated viral vector production
    O-W Merten
    C Gény-Fiamma
    A M Douar
    Gene Therapy, 2005, 12 : S51 - S61
  • [10] Current issues in adeno-associated viral vector production
    Merten, OW
    Gény-Fiamma, C
    Douar, AM
    GENE THERAPY, 2005, 12 (Suppl 1) : S51 - S61